BTMD biote
- 5.980
- -0.160-2.61%
- 5.690
- -0.290-4.85%
biote News
10-Q: Q3 2024 Earnings Report
8-K: Biote Reports Third Quarter 2024 Financial Results Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages
10-Q: Q2 2024 Earnings Report
8-K: Biote Reports Second Quarter 2024 Financial Results Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance
10-Q: Q1 2024 Earnings Report
biote | 10-K: FY2023 Annual Report
biote | 10-Q: Q3 2023 Earnings Report
biote | 8-K: Biote Reports Third Quarter 2023 Financial Results Achieves Progress in Test of Complementary Wellness Therapeutics Reiterates 2023 Financial Guidance
Biote | 10-Q: Q2 2023 Earnings Report
Biote | 8-K: Biote Reports Second Quarter 2023 Financial Results Solid Second Quarter Revenue Growth Continued Progress to Optimize Capital Structure and Enhance Share Liquidity Expansive Strategic Approach Targeting Therapeutic Wellness and Mens Health C
Biote | 10-Q: Quarterly report
Biote | 8-K: Biote Reports First Quarter 2023 Financial Results New Initiative Targets Long-term Growth Opportunity in Mens Health Company Launches Warrant Exchange Offer and Consent Solicitation Maintains 2023 Financial Guidance
biote | 10-K: FY2022 Annual Report
biote | 10-Q/A: FY2022 Annual Report
biote | 10-Q/A: FY2022 Annual Report
Biote | 10-Q: Q3 2022 Earnings Report
Biote | 8-K: Biote Reports Third Quarter Financial Results Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance
Biote | 10-Q: Q2 2022 Earnings Report
Biote Corp | 8-K: Biote Reports Second Quarter 2022 Financial Results
Haymaker Acquisition Corp II | 10-Q: Q1 2022 Earnings Report
Analysis
Price Target
No Data
No Data